TSE:MFC

Manulife Financial (MFC.TO)

57.04
+0.49 (0.87%)
as of Jun 25, 2026, 8:00:00 pm Market Open.
1634 watching
0
Investor Insights
star iconJun 25, 2026, 12:00 am

This summary was created by AI, based on 28 opinions in the last 12 months.

Manulife Financial (MFC) has garnered mixed opinions from market experts. Many analysts recognize MFC's potential, particularly highlighting its growth in Asia and successful capital generation from legacy businesses. The consensus seems to indicate a solid long-term investment due to its steady dividend yield, with several experts suggesting that patience may be required as the stock navigates short-term fluctuations. Despite some concerns about past performance and market positioning against competitors, the company's strategy and management is viewed positively. Analysts mention the current valuation as reasonable compared to peers, suggesting MFC is a better option for income rather than growth. Overall, there is a cautious optimism about MFC's capabilities and future direction.

consensus icon
Consensus
Hold
valuation icon
Valuation
Fair Value
review icon
Similar
SLF-T
BUY
A boring value style dividend paying stock, but where you end up with superior performance because a large portion of your return is from the dividends which are tax effective.
BUY
A good long term growth story in the financial sector. A dominant company in the index. Prefers over the banks.
BUY
Likes this company and the fee revenue they are generating. Probably a higher growth rate than with the banks.
BUY
Manulife and Sun Life have the capacity to increase their dividends more than the banks, which would be a good alternative to the banks.
DON'T BUY
The integration with John Hancock is going quite well. Too expensive. Would prefer 15/20% cheaper. Feels the street is too optimistic about their future profitability.
TOP PICK
Management has done a remarkable job in growing the company.Savings from the John Hancock takeover is going to be $325 million rather than $255 million. Could take over a bank down the road.
BUY
Likes both Sun Life and Manufacturers Life. Both have more room to increase their dividend payout ratio than the Cdn banks.
BUY
Has pulled back a little along with Cdn financials probably due to higher interest rate concerns. Not a bad entry point. Expects 10% upside including dividends. Very solid company.
BUY ON WEAKNESS
A very strong company. Can't see anything in the Eliot Spitzer investigation that will materially impact the company. Has a large US component, so some currency risk. Low $50's is a good entry point.
BUY ON WEAKNESS
Has been caught in a bit of a downdraft because of the bank reports. Asian operations are starting to fire. Wait until the banking reporting season is over and buy on dips.
BUY
Their #1 in the financial sector. Cash flow yield is 16%. Has a good growth potential with their John Hancock acquisition and their Asian activity. Well run.
WATCH
Currently evaluating. John Hancock acquisition was good. Latest quarterly earnings were disappointing. Expensive relative to other insurance companies but has a better growth profile.
BUY
Prefers Manulife over Sun Life as it has a little bit better growth rate. Trading close to its highs. Good international growth.
BUY
Still in an uptrend. The life companies have one more leg in them. Use a stop/loss of $50/52 in case of a reversal.
BUY
Sees tough sledding for banks growth, so prefers life companies. Likes their Asian exposure where sales are growing at a very heavy rate.
Showing 1,966 to 1,980 of 2,281 entries